Logo

Debiopharm's Debio 1143 Receives the US FDA's Breakthrough Therapy Designation for Front-Line Treatment of Head and Neck Cancer

Share this
Debiopharm's Debio 1143 Receives the US FDA's Breakthrough Therapy Designation for Front-Line Treatment of Head and Neck Cancer

Debiopharm's Debio 1143 Receives the US FDA's Breakthrough Therapy Designation for Front-Line Treatment of Head and Neck Cancer

Shots:

  • The BTD is based on P-II results that demonstrated improvement of the 1EPs locoregional control rate @18mos. after CRT (21% improvement vs. control arm) and a marked PFS benefit vs the CRT + PBO arm after a 2-year follow-up period
  • The BTD reaffirms that Debio 1143 has the potential to offer benefit over the current SOC in LA-SCCHN- responding to the high unmet need in this debilitating cancer type
  • Debio 1143 is a potential first-in-class oral antagonist of IAPs- sensitizes tumor cells to radio-CT by promoting programmed cell death and fostering anti-tumor immunity

 ­ Ref: PRNewswire | Image: Debiopharm

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions